|
|||||
Indian drugmakers anticipate a mixed third quarter. Domestic sales and new specialty drugs will drive growth. US generics will see new product boosts. Contract services and APIs are set for moderate gains. Sun Pharma and Lupin are poised for leadership. Cipla and Dr Reddy's face softer US sales. Divi's Laboratories expects strong custom synthesis growth.
Category:
News and Media
Mutual fund managers adjusted portfolios in December, buying Swiggy and Zomato amid underperformance and favoring Tata Consultancy Services over Infosys. They also rotated allocations in InterGlobe Aviation following a selloff due to mass flight cancellations, preparing for the Q3 results season.
Category:
News and Media
Fitch's top sovereign analyst warned that a significant erosion of the Federal Reserve's independence would negatively impact the US credit rating. The primary concern is any indication that the dollar's global reserve currency status could diminish, following an investigation into Fed Chair Jerome Powell.
Category:
News and Media
All news |
||||||||||||||||||
|
||||||||||||||||||